Factors influencing the efficacy of programmed cell death protein 1 / programmed death-ligand 1 inhibitors in non-small cell lung cancer
Current evidence supports PD-L1 as the most widely implemented biomarker, but no single factor adequately captures the biological and temporal heterogeneity of treatment response, so integrated, dynamic, and context-specific biomarker models are required to improve precision immuno-oncology.
Longhua Lu, Ze-Yang Zeng, Zi-Qi Guan et al.
· Journal of Clinical Question · 0 citations